AdventHealth Research Institute Non-Alcoholic Fatty Liver Disease Biobank and Registry (AVAIL) (NCT04807868)
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to create a resource that will advance research that is focused on discovery of novel therapies, risk stratification, and aggressive interventions for those at highest risk for non-alcoholic fatty liver disease (NAFLD). To achieve this, we will generate a biobank of liver tissue collected during standard of care liver biopsies. Paired blood/urine samples, FibroScan and relevant data will also be collected.
Who can join: Review the eligibility criteria below.
Location: AdventHealth Translational Research Institute — Orlando, Florida
Age range: 18 Years
🧪 Interventions in This Study
- Standard of care liver biopsy (PROCEDURE)
- Fibroscan (OTHER)
- Biospecimen Collection (OTHER)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- AdventHealth Translational Research Institute — Orlando, Florida
📞 Contact the Study Coordinator
Phone: (407) 303-7100
Email: Fh.tri.recruitment@adventhealth.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Non-Alcoholic Fatty Liver Disease
- Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis — Chula Vista, California
- Role of Immune System in Obesity-related Inflammation and Cardiometabolic Risk — St Louis, Missouri
- A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017) — Chandler, Arizona
- A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE) — Birmingham, Alabama
- SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver Disease — Chicago, Illinois
- The Olmsted NAFLD Epidemiology Study (TONES) — Rochester, Minnesota
Explore by condition: All Non-Alcoholic Fatty Liver Disease clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.